Targeting master regulators to overcome AR-driven resistance in advanced prostate cancer
Official title: Therapeutic targeting of master regulators in non-canonical AR driven advanced lethal prostate cancers
Funded at State University of New York at Buffalo · NIH-11369845 · Data updated 2026-11-12
This grant explores how cancer cells rewire their growth signals to resist AR-targeted therapies in advanced prostate cancer and tests new ways to block those master regulators.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project start | August 10, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $526,549 |
| NIH project number | 5R37CA272726-04 |
| Project ID | NIH-11369845 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with advanced castration-resistant prostate cancer who have progressed on AR-targeted therapies may benefit from downstream strategies developed in this research.
✕Less likely to help
Patients without AR-driven resistance mechanisms or those not eligible for future clinical testing may not directly benefit.
What this research studies
If you or a loved one has advanced prostate cancer that no longer responds to AR-targeted drugs, this project looks at the key transcription factors driving that resistance. Researchers will study how these master regulators interact with the androgen receptor and contribute to tumor survival, using preclinical models and molecular analyses. The goal is to identify new targets that could restore sensitivity to treatment and slow disease progression. Findings could guide future therapies to help patients delay or overcome resistant disease.
Why it matters
Potential benefit: If successful, the work could lead to new treatments that prevent or reverse resistance to current AR-targeted therapies, potentially prolonging survival and quality of life.
How similar studies have gone: Preclinical data suggest that manipulating master regulatory transcription factors can reverse resistance in models, supporting a promising but early-stage approach.
Where this research is happening
-
State University of New York at Buffalo
Amherst, United States Active
Researchers
- Principal investigator: Adelaiye-Ogala, Remi — State University of New York at Buffalo
- Study coordinator: Adelaiye-Ogala, Remi
Related research
Other NIH-funded projects on the same topics.
-
Ariginine-depleting therapy plus chemotherapy for aggressive variant prostate cancers
This project tests whether removing arginine from the body enhances chemotherapy for men with a difficult-to-treat prostate cancer subtype.
-
Lowering arginine with chemotherapy for aggressive prostate cancer
Looks at whether lowering a nutrient called arginine together with platinum‑taxane chemotherapy can help men with aggressive, treatment‑resistant prostate cancer.
-
Targeting key regulators in advanced prostate cancer that resist standard treatments
This research looks for new ways to treat advanced prostate cancer that has stopped responding to common hormone therapies.
-
Investigating the impact of arginine depletion with chemotherapy in aggressive prostate cancers
This study is looking at how lowering levels of an amino acid called arginine might make chemotherapy work better for men with aggressive prostate cancer that doesn't respond well to regular treatments.
-
Targeting DNA repair pathways in prostate cancer
This study is looking at whether a special combination of treatments can help men with non-castrate prostate cancer, especially those with certain genetic changes, by focusing on fixing DNA damage to improve their chances of recovery.
-
Targeting key factors in advanced prostate cancer treatment resistance
This study is looking at how certain proteins in prostate cancer cells help the cancer resist treatments that target hormones, with the goal of finding new ways to improve treatment for patients who aren't responding to current therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.